Last Updated:
Create account to add to watchlist!

HH&L Acquisition Co. - HHLA

  • Commons



    HHLA Vol: 228.3K

  • Warrants



    HHLA+ Vol: 3.7K

  • Units



    HHLA= Vol: 1.6K

Average: 0
Rating Count: 0
You Rated: Not rated

Please log in to rate.

SPAC Stats

Market Cap: 404.5M
Average Volume: 79.8K
52W Range: $9.60 - $10.00
Weekly %: +0.41%
Monthly %: +0.41%
Inst Owners: 69


Target: Searching
Days Since IPO: 296
Unit composition:
Each unit has an offering price of $10.00 and consists of one Class A ordinary share and one-half of one redeemable warrant
Trust Size: 30000000.0M


Our officers and directors are as follows: Name ​ ​ Age ​ ​ Position ​ Kenneth W. Hitchner ​ ​ 60 ​ ​ chairman of the board ​ Richard Qi Li ​ ​ 50 ​ ​ chief executive officer & director of the board ​ Huanan Yang ​ ​ 36 ​ ​ chief operating officer & director of the board ​ Yingjie (Christina) Zhong ​ ​ 52 ​ ​ chief financial officer ​ Qingjun Jin ​ ​ 63 ​ ​ independent director nominee ​ Dr. Jingwu Zhang Zang ​ ​ 64 ​ ​ independent director nominee ​ Kenneth W. Hitchner, 60, the chairman of our board, brings a wealth of financial services experience through a 28-year career at Goldman Sachs. Mr. Hitchner began his career at Goldman Sachs in New York City, United States in 1991 in the investment banking division and became a partner in 2002. Over the course of his career at Goldman Sachs from 1991 to 2019, Mr. Hitchner held various leadership positions in creating and growing several key business units spanning industry verticals and multiple geographies. Prior to his retirement from Goldman Sachs, Mr. Hitchner served as the chairman and chief executive officer of Goldman Sachs in Asia Pacific Ex-Japan and a member of Goldman Sachs’ Global Management Committee. Mr. Hitchner was a founding member of Goldman Sachs’ healthcare banking group, which he joined in 1995. He later on served as global head of the healthcare banking group and global co-head of the technology, media and telecom Group. Following his relocation to Hong Kong in 2013, Mr. Hitchner, in his capacity as the chairman and chief executive officer of Goldman Sachs in Asia Pacific Ex-Japan, provided oversight to a number of significant transactions leveraging his extensive knowledge and experience in leading healthcare transactions, particular in the biotech sector, as well as technology related transactions. As part of his leadership role at Goldman Sachs Asia, Mr. Hitchner drove business initiatives to capitalize on new economy trends with a focus on the healthcare sector and further developed and grew Goldman Sachs’ Asia business overall. Mr. Hitchner currently serves as a board member of Shanghai-based Wuxi Biologics (Cayman) Inc. and a senior advisor to Wuxi AppTec Co., Ltd., two of China’s leading healthcare companies. Mr. Hitchner also serves as an independent director of Provident Acquisition Corp., a newly incorporated blank check company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Although Mr. Hitchner has retired from Goldman Sachs and no longer holds any management or employment position at Goldman Sachs, he has an honorary title of senior director of Goldman Sachs. Richard Qi Li, 50, our chief executive officer and director, has more than two decades of experience in investments, capital markets, corporate finance, and risk management. Until his resignation in December 2020 which is expected to take effect shortly, Mr. Li had been, from 2017, the chief investment officer and, from 2019, the chief operating officer of China Great Wall AMC (International) Holdings Ltd. and, from 2018, the chief executive officer of Great Wall Pan Asia Asset Management Ltd., both subsidiaries of China Great Wall Asset Management Co. Ltd., a leading asset management company based in China. Mr. Li was previously a managing director and the head of China securities at Goldman Sachs Asia from 2013 to 2017, and worked at Deutsche Bank Hong Kong from 2003 to 2013, including as a managing director and the head of north Asia capital markets and treasury solutions. Mr. Li has also worked at Merrill Lynch, the World Bank, and the Ministry of Finance of the PRC. Mr. Li’s experience in the healthcare sector includes investments in two top-tier European healthcare businesses and WeDoctor, which is one of China’s top-tier online healthcare companies. He has also been involved in investments in the e-commerce, consumer, energy and real estate sectors in Asia and globally. Mr. Li also has experience leading several significant capital raising transactions. Mr. Li obtained a bachelor’s degree in mathematics and a master’s degree in economics from Nankai University in China and a master of business administration from Columbia Business School. He was also a visiting scholar at Harvard University in 2019. 120 TABLE OF CONTENTS Huanan Yang, 36, our chief operating officer and director, currently serves as an executive director of HOPU Investments, where he is primarily responsible for sourcing, structuring and executing late stage growth as well as buyout investment opportunities. He also shares broad portfolio management responsibilities including strategy, executive recruiting, financing, restructuring, business development and other corporate matters. Mr. Yang acts as board member and observer of several of portfolio companies of HOPU Investments. Prior to joining HOPU Investments in 2014, Mr. Yang worked in the Asia Growth Fund of The Carlyle Group in 2013, and previously served in a corporate development role at the MAERSK Group from 2009 to 2012. Mr. Yang obtained a bachelor's degree in electrical engineering from Fudan University in China, a master’s degree of engineering from Dartmouth College and a MBA degree from Harvard Business School. Yingjie (Christina) Zhong, 52, our chief financial officer, has significant experience in investment banking and finance. From 2008 to 2017, Ms. Zhong served as the head of China Financial Institution Group and was a managing director in the Investment Banking Department at Morgan Stanley Asia Ltd. She previously worked as an executive director in the investment Banking Department at Goldman Sachs based in Beijing from 2005 to 2008. From 2000 to 2005, Ms. Zhong was a vice president in the Investment Banking Department at China International Capital Corporation Limited. She formerly worked at the National Audit Office of The People’s Republic of China from 1990 to 1998. Ms. Zhong holds a bachelor’s degree of economics in auditing from Wuhan University in China and a master’s degree of business administration from China Europe International Business School. She is a Certified Public Accountant of China and a holder of certificates of accounting and finance from the Association of Chartered Certified Accountants. She was a visiting professor of China Capital University of Economics and Business in 2012. Ms. Zhong was also a deputy director of the 10th Beijing Economics Committee of China Democratic National Construction Association. Qingjun Jin, 63, will serve as our independent director immediately upon the effectiveness of our registration statement on Form S-1, of which this prospectus is a part. Mr. Jin is currently and has been a senior partner at King & Wood Mallesons since 2002, where his practice focuses on corporate finance, capital market and bankruptcy. Mr. Jin currently serves and has served as a director of Goldstream Investment Limited since 2019, a director of Shenzhen Cheng Chung Design Co., Ltd. since 2018, a director of Shenzhen Kingkey Smart Agriculture Times Co., Ltd. since 2018, a director of Bank of Tianjin Co., Ltd. since 2017, a director of Hengqin Life Insurance Co., Ltd. since 2017, a director of Central Development Holdings Limited since 2017, a director of Sino-Ocean Group Holding Limited Since 2016, a director of Times China Holdings Limited since 2015, a director of Guotai Junan Securities Co., Ltd. since 2013 and a director of Invesco Great Wall Fund Management Co., Ltd. since 2003. Previously, Mr. Jin had served as a director of CSG Holding Co., Ltd. from 2016 to 2019, a director of Konka Group Co., Ltd. from 2015 To 2018, a director of Gemdale Corporation from 2014 to 2017, a director of Dagang Holding Group Co., Ltd. from 2015 to 2016, a director of Materwork Group Co., Ltd. from 2013 to 2016 and a director of New China Assets Management Co., Ltd. from 2010 to 2016. Mr. Jin obtained a bachelor’s degree from Anhui University in 1982 and an LL.M. degree from the Graduate School of China University of Political Science and Law in 1987. He was a research fellow at Harvard Kennedy School of Government in 2009. Before joining King & Wood Mallesons in 2002, Mr. Jin served as a lawyer in JSM Hong Kong, Clyde & Co., London and Beijing C&C law firm from 1987 to 1993, and was the founding partner of Shenzhen Shu Jin Law Firm from 1993 to 2002. Dr. Jingwu Zhang Zang, 64, will serve as our independent director immediately upon the effectiveness of our registration statement on Form S-1, of which this prospectus is a part. Dr. Zang is the founder, honorary chairman and director of I-Mab. Prior to founding I-Mab, Dr. Zang served as the chief scientific officer and president of Simcere Pharmaceutical Group and BioScikin Co., Ltd. from 2013 to 2016. Dr. Zang held senior management positions at GlaxoSmithKline (GSK), as the global senior vice president and head of GSK’s Research and Development in China, from 2007 to 2013. The academic career of Dr. Zang started at Dr. Willems Institute and University of Limburg in Belgium in 1990. Dr. Zang was a professor at Baylor College of Medicine in Houston from 1996 to 2002 and later joined the Chinese Academy of Sciences as the founding director of the Institute of Health Sciences and as a co-director of Institute Pasteur Shanghai, an independent nonprofit life science institute to address public health problems in China, where he served as its director from 2004 to 2006. Dr. Zang also served as a director of Shanghai Institute of Immunology from 2002 to 2007. Dr. Zang received his M.D. 121 TABLE OF CONTENTS from Shanghai Second Medical University (now part of Shanghai Jiaotong University in China) in 1984, and his Ph.D. in neuroimmunology from the University of Brussels in Belgium in 1990. Dr. Zang conducted his post-doctoral work at Harvard Medical School in 1992, and obtained his U.S. medical license from the Texas Medical Board through a clinical residency at Baylor College of Medicine in Houston in 1999. Advisory Board We have established an advisory board, the role and functions of which will be determined by the board of directors from time to time. We currently expect our advisory board to, upon the request of the directors, provide its business insights (i) in sourcing potential business combination targets, (ii) when we assess potential business combination targets and (iii) as we work to create additional value in the business or businesses that we acquire. The role of the advisory board is consultative in nature to support our directors and officers in operating our business, and it will not perform managerial board or committee functions. Members of the advisory board will not be subject to the fiduciary requirements to which our board of directors are subject, nor will advisory board members have any internal voting or decision making role, or any authority to act on our behalf. The board of directors is not required to follow any advice, comments or recommendations of the advisory board in relation to the matters described herein. We have not entered into any agreements governing our relationship with any members of our advisory board, and we may modify or expand our roster of advisory board members as we source potential business combination targets or work to create value in the business or businesses that we acquire. Mr. Fenglei Fang is currently the chairman and sole member of the advisory board. Fenglei Fang, 68, the chairman of our advisory board, is a highly regarded investor with a long and distinguished track record of delivering stockholder value. Mr. Fang is the founder and chairman of HOPU Investments, director of Goldman Sachs Gao Hua Securities Company Limited and chairman of Beijing Gaohua Securities Company Limited. Previously, he served as deputy chief executive of China International Capital Corporation (CICC) from 1995 to 2000, Chief Executive Officer of BOC International Holdings Ltd from 2000 to 2001 and Chief Executive Officer of ICEA Finance Holdings Limited from 2002 to 2003. In addition to the transactions he has led at HOPU Investments, Mr. Fang was involved in a number of high-profile transactions as part of his positions at Goldman Sachs Gao Hua Securities Company Limited and China International Capital Corporation (CICC) such as China Telecom’s acquisition of equity stakes in Hong Kong Telecom, the initial public listings of China Mobile, China Telecom, China Unicom, China Netcom, PetroChina and Sinopec, and Pacific Century Cyber Works’ acquisition of Hong Kong Telecom and China National Offshore Oil Corporation's acquisition of a major oilfield in Nigeria. Mr. Fang was recognized as one of the “Top Ten Influential Leaders of China’s Capital Market” in 2003 by Financial Asia and was awarded “Asian Financial Service Development Outstanding Achievement”in 2008 by Euromoney. He is also the Vice-Chairman of the Board of Teach for China, China Advisory Board Member for the Lincoln Center for the Performing Arts, and International Committee Member for the Kennedy Center for the Arts. Mr Fang is also founder of the Duancun School in Hebei and the Fuxi School in Gansu. Mr. Fang graduated from Zhongshan (Sun Yat-sen) University with a B.A. in Chinese and Economics. He also received an Executive Education certificate from Harvard Business School’s Advanced Management Program. Number and Terms of Office of Officers and Directors Our board of directors consists of five members and is divided into three classes with only one class of directors being appointed in each year, and with each class (except for those directors appointed prior to our first annual general meeting) serving a three-year term. In accordance with NYSE corporate governance requirements, we are not required to hold an annual meeting until one year after our first fiscal year end following our listing on NYSE. The term of office of the first class of directors, consisting of two independent directors to be identified and appointed, will expire at our first annual general meeting. The term of office of the second class of directors, consisting of Mr. Richard Qi Li, Dr. Jingwu Zhang Zang and Mr. Qingjun Jin, will expire at the second annual meeting of shareholders. The term of office of the third class of directors, consisting of Mr. Kenneth W. Hitchner and Mr. Huanan Yang, will expire at the third annual general meeting. 122 TABLE OF CONTENTS Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint officers as it deems appropriate pursuant to our amended and restated memorandum and articles of association. Director Independence The rules of the NYSE require that a majority of our board of directors be independent within one year of our initial public offering. An “independent director” is defined generally as a person who, in the opinion of the company’s board of directors, has no material relationship with the listed company (either directly or as a partner, shareholder or officer of an organization that has a relationship with the company). Upon the effectiveness of the registration statement of which this prospectus forms a part, we expect to have two “independent directors” as defined in the NYSE rules and applicable SEC rules prior to completion of this offering. Our board of directors has determined that each of Mr. Qingjun Jin and Dr. Jingwu Zhang Zang is an “independent director” as defined in the NYSE listing standards and applicable SEC rules. Our independent directors will have regularly scheduled meetings at which only independent directors are present. Officer, Director and Advisory Board Member Compensation None of our officers, directors or advisory board member have received any cash compensation for services rendered to us. Commencing on the date that our securities are first listed on NYSE through the earlier of consummation of our initial business combination and our liquidation, we will pay our sponsor $15,000 per month for office space, utilities, and secretarial and administrative services provided to us. In addition, our sponsor, officers, directors and advisory board members or any of their respective affiliates will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that were made to our sponsor, officers or directors or members of our advisory board, or our or their affiliates. Any such payments prior to an initial business combination will be made from funds held outside the trust account. Other than quarterly audit committee review of such reimbursements, we do not expect to have any additional controls in place governing our reimbursement payments to our directors and officers for their out-of-pocket expenses incurred in connection with our activities on our behalf in connection with identifying and consummating an initial business combination. Other than these payments and reimbursements, no compensation of any kind, including finder’s and consulting fees, will be paid by the company to our sponsor, officers and directors, or any of their respective affiliates, prior to completion of our initial business combination. After the completion of our initial business combination, directors or members of our management team who remain with us may be paid consulting or management fees from the combined company. All of these fees will be fully disclosed to shareholders, to the extent then known, in the proxy solicitation materials or tender offer materials furnished to our shareholders in connection with a proposed initial business combination. We have not established any limit on the amount of such fees that may be paid by the combined company to our directors or members of management. It is unlikely the amount of such compensation will be known at the time of the proposed initial business combination, because the directors of the post-combination business will be responsible for determining officer and director compensation. Any compensation to be paid to our officers will be determined, or recommended to the board of directors for determination, either by a compensation committee constituted solely by independent directors or by a majority of the independent directors on our board of directors. We do not intend to take any action to ensure that members of our management team maintain their positions with us after the consummation of our initial business combination, although it is possible that some or all of our officers and directors may negotiate employment or consulting arrangements to remain with us after our initial business combination. The existence or terms of any such employment or consulting arrangements to retain their positions with us may influence our management’s motivation in identifying or selecting a target business but we do not believe that the ability of our management to remain with us after the consummation of our initial business combination will be a determining factor in 123 TABLE OF CONTENTS our decision to proceed with any potential business combination. We are not party to any agreements with our officers and directors that provide for benefits upon termination of employment. Committees of the Board of Directors Upon the effective date of the registration statement of which this prospectus forms a part, our board of directors will have three standing committees: an audit committee, a c

Holder Stats

1 0
% of Shares Held by All Insider 0.00%
% of Shares Held by Institutions 60.05%
% of Float Held by Institutions 60.05%
Number of Institutions Holding Shares 69

Mutual Fund Holders

Holder Shares Date Reported Value % Out
Saba Capital Income & Opportunities Fd 29541 2021-08-30 285956 0.07

Institutional Holders

Reporting Date Hedge Fund Shares Held Market Value % of Portfolio Quarterly Change in Shares Ownership in Company
2021-11-15 Berkley W R Corp 129,363 $1,260,000 0.1% 0 0.250%
2021-11-15 CSS LLC IL 41,458 $400,000 0.0% 0 0.080%
2021-11-15 Hunting Hill Global Capital LLC 402,813 $3,920,000 1.2% 0 0.778%
2021-11-15 Dark Forest Capital Management LP 366,169 $3,560,000 1.3% 0 0.708%
2021-11-15 HighTower Advisors LLC 1,006,785 $9,790,000 0.0% -0.5% 1.945%
2021-11-12 Weiss Asset Management LP 200,000 $1,940,000 0.0% 0 0.386%
2021-11-09 Basso Capital Management L.P. 393,856 $3,830,000 0.4% +1,134.7% 0.761%
2021-08-13 Senator Investment Group LP 750,000 $7,280,000 0.1% +50.0% 1.449%
2021-08-13 RP Investment Advisors LP 2,186,917 $21,210,000 2.8% -33.3% 4.226%
2021-08-13 Basso Capital Management L.P. 31,900 $310,000 0.0% 0 0.062%
2021-08-13 Qube Research & Technologies Ltd 25,885 $250,000 0.0% 0 0.050%
2021-08-06 HighTower Advisors LLC 1,011,406 $9,820,000 0.0% 0 1.954%
2021-08-05 III Capital Management 100,000 $970,000 0.1% 0 0.193%
2021-05-05 Valliance Asset Management Ltd 800,000 $8,080,000 100.0% 0 6.561%
2021-05-03 Infini Master Fund 100,000 $110,000 0.6% 0 0.820%

SEC Filings

Form Type Form Description Filing Date Document Link
10-Q FORM 10-Q 2021-11-12
10-Q FORM 10-Q 2021-08-05
10-Q FORM 10-Q 2021-05-24
NT 10-Q NT 10-Q 2021-05-17
8-K 8-K 2021-03-26
SC 13G SCHEDULE 13G 2021-02-18
8-K FORM 8-K 2021-02-16
8-K FORM 8-K 2021-02-09
424B4 424B4 2021-02-08
EFFECT 2021-02-04
S-1MEF S-1MEF 2021-02-04
8-A12B FORM 8-A12B 2021-02-04
CORRESP 2021-02-02
CORRESP 2021-02-02
CORRESP 2021-02-01
S-1/A S-1/A 2021-02-01
UPLOAD 2021-01-29
CORRESP 2021-01-20
S-1 S-1 2021-01-20
UPLOAD 2020-10-14
DRS 2020-09-16